ASLAN Pharma Raises $23 Million In Pre-IPO Round

ASLAN Pharma of Singapore raised $23 million in a pre-IPO financing round. The company is currently developing four immunotherapies and targeted agents for tumor types prevalent in Asia. According to media reports, the IPO will be held in Asia (possibly Taipei) or the US, and could take place as early as this year. ASLAN has raised over $100 million to date. The company's lead drug, varlitinib, is a pan-HER inhibitor currently in three separate Phase II trials. More details.... Share this with colleagues: // //